RAC1 and hepatocellular carcinoma: Given that activation of MAPK signaling contributes to the resistance to multiple chemotherapies, especially is responsible for the resistance to sorafenib treatment for HCC, thus we further investigated whether blocking MAPK signaling by MG53-mediated RAC1 inhibition could reverse the resistance of HCC cells to sorafenib treatment.